Severe Depression Clinical Trial
— Psilo101Official title:
Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression
The main aim of the study is to investigate the possible long-term therapeutic effects of psilocybin on the symptoms of severe depression, as well as the brain mechanisms underlying these changes. Depression severity is assessed before and after (i.e., 1 week, 3 months and 6 months after) a single dose of psilocybin and compared to respective scores of a group receiving an active placebo, ketamine. Brain activity (using functional magnetic resonance imaging) is measured before and one week after drug administration in order to determine whether changes in brain networks related to emotional and self-referential processing correlate with any observed changes in depression scores. Further, blood samples will be obtained from the participants and analyzed in order to reveal gene expression and molecular level correlates underlying rapid antidepressant effects, and to identify biomarkers that predict treatment outcome.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | September 2021 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility |
Inclusion Criteria: 1. Major depression of a moderate to severe degree (17+ on the 21-item HAM-D). 2. No health-related contraindications. Exclusion Criteria: 1. Current or previously diagnosed psychotic disorder. 2. Immediate family member with a diagnosed psychotic disorder. 3. Medically significant condition rendering unsuitability for the study (e.g., diabetes, epilepsy, severe cardiovascular disease, hepatic or renal failure etc.). 4. History of suicide attempts. 5. History of mania. 6. Current 5-HT2A antagonist antidepressant medication. 7. Blood or needle phobia. 8. Positive pregnancy test. 9. Current drug or alcohol dependence. 10. Lack of appropriate use of contraception. 11. Breast-feeding. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Helsinki University | Dr. Robin Carthart-Harris and Prof. David Nutt, Imperial College London, UK, Dr. Tomi Rantamäki, Laboratory of Neurotherapeutics, Department of Biosciences, University of Helsinki |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The 16-Item Quick Inventory of Depressive Symptomatology (QIDS) | The primary outcome measures in this study will be the mean change in QIDS scores from pre-administration baseline at day 1 to Follow-up 2 at day 103 (3 months after the administration session). Additionally, an electronic version of the QIDS will be performed 6 months after the administration session. The criteria for determining response will be a reduction of 25% in the (QIDS; Rush et al., 2003) scores from baseline (screening), and remission will be scores of =5 on the QIDS. | 6 months | |
Secondary | The Montgomery and Asberg Depression Rating Scale | The Montgomery and Asberg Depression Rating Scale will be carried out at screening ( day 1), Follow-up 1 (day 18) and Follow-up 2 (day 103, 3 months after the administration session). | 3 months | |
Secondary | Hamilton Depression Rating Scale | The Hamilton Depression Rating Scale will be carried out at screening ( day 1), Follow-up 1 (day 18) and Follow-up 2 (day 103, 3 months after the administration session). | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04618250 -
Improving Physical Health in Patients With Psychiatric Disorders in General Practice (SOFIA)
|
N/A | |
Completed |
NCT02957591 -
Probiotic Supplementation in Severe Depression
|
N/A | |
Recruiting |
NCT05842278 -
The Dosage Effect of pBFS Guided rTMS Treatment for MDD
|
N/A | |
Not yet recruiting |
NCT05957341 -
pBFS Guided 20min Inter-session Interval rTMS Treatment for MDD
|
N/A | |
Recruiting |
NCT05964036 -
pBFS-guided High-dose TMS Over DMPFC for Treatment-resistant Major Depressive Disorder
|
N/A | |
Recruiting |
NCT03862209 -
Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health (RECOVER-E) Croatia
|
N/A | |
Active, not recruiting |
NCT03892473 -
Community-based Mental Health Care for People With Severe and Enduring Mental III Health ( RECOVER-E )
|
N/A | |
Active, not recruiting |
NCT03837340 -
Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health
|
N/A | |
Enrolling by invitation |
NCT03922425 -
Community-based Mental Health Care for People With Severe and Enduring Mental III Health
|
N/A | |
Recruiting |
NCT06112652 -
Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique
|
N/A | |
Completed |
NCT02522377 -
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
|
N/A | |
Completed |
NCT02715986 -
Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy
|
N/A |